Deliver Your News to the World

BASF and Glycosyn leverage IP to successfully remove Glycom’s HMO products for IBS management from


BASF and Glycosyn announced its recent success in delisting Human Milk Oligosaccharide (HMO) products for Irritable Bowel Syndrome (IBS) applications from in the United States. BASF filed the infringements using the Amazon Utility Patent Neutral Evaluation Procedure[1] based on BASF’s in-licensed US Patent No. 10,098,903.

BASF requested the delisting of Glycom’s HoligosTM IBS and HoligosTM IBS Restore products from At the time of this press release, the above-mentioned products were no longer available on

BASF holds the in-licensed patents and expertise knowledge from Glycosyn that relate to 2′-Fucosyllactose (2′-FL)[2] for gastrointestinal health. Glycosyn is a world leading technology company specializing in the development of HMOs. Glycosyn has established and owns unique intellectual property and know-how in the production and use of HMOs for the benefit of improving gastrointestinal health of adults.

PREBILAC®, BASF’s own brand of 2’-FL, was launched in 2019 for digestive health. BASF is working in close collaboration with customers to commercialize 2’-FL dietary supplements to support the digestive health of consumers. Emerging scientific evidence show that 2’-FL supports the development and maintenance of a healthy gut microbiome and immune system. The prebiotic functions of 2’-FL support human gastrointestinal health and acts as an anti-inflammatory agent for managing inflammatory disorders of the gut such as IBS.

BASF respects the intellectual property of other companies and individuals. This exercise is part of BASF’s ongoing commitment in protecting and enforcing its own and in-licensed intellectual properties.

[1] This procedure enables patent holders to request the removal of Amazon listings for products that they believe infringe their patents.

[2] 2’-FL is a component of HMO, complex carbohydrates that are naturally present in breast milk. For the majority of mothers, 2’-FL is the most abundant HMO in their breast milk.

About BASF’s Nutrition & Health division 

BASF Nutrition & Health provides a comprehensive product and service portfolio for the human and animal nutrition, pharmaceutical, ethanol and flavor & fragrance industries. Together with our customers, we play an active role in enhancing the nutrition, health and wellbeing of consumers all over the world. Our products fulfill the highest safety, regulatory and sustainability standards. Our human nutrition solutions include vitamins and carotenoids, plant sterols, lutein and sterol esters, emulsifiers, high-concentrated omega-3 fatty acids, human milk oligosaccharide and peptides. Vitamins and carotenoids also form an important part of our animal nutrition portfolio, as do other feed additives such as trace elements, enzymes and organic acids. We provide the pharmaceutical industry with a broad range of excipients and selected large-volume active pharmaceutical ingredients such as ibuprofen and omega-3 fatty acids. Leveraging our advanced technology, we create high performance industrial enzymes for different markets, such as ethanol production. Furthermore, we offer aroma ingredients such as citral, geraniol and L-menthol. BASF Nutrition & Health operates sites in Europe, North America, South America and in Asia-Pacific. For more information, go to


About BASF

At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 117,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €59 billion in 2019. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the U.S. Further information at


About Glycosyn

Glycosyn LLC is a biotechnology-based therapeutics, diagnostics and dietary supplement company, whose mission is to enhance health. Glycosyn develops efficient and cost-effective technologies for synthesizing and producing Human Milk Oligosaccharides (HMOs), major health-giving components of human milk. Glycosyn owns exclusive rights for the use of HMOs in treating Inflammatory Bowel Disease and Irritable Bowel Syndrome, and for the use of HMOs as prebiotics, with other patents in process. Glycosyn Health Initiatives (GHI) is a non-profit dedicated to bringing the benefits of HMOs to those who need them most in the developing world. Further information at

( Press Release Image: )


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.